Without a doubt, the brightest star in the summer night sky is Arcturus. It’s the second-brightest star in our night skies throughout the year. Only Sirius, the brightest star in the constellation ...
Hosted on MSN
Arcturus outlines 12-week cystic fibrosis study launch in 2026 amid cost controls and delayed KOSTAIVE BLA
Earnings Call Insights: Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2025 CEO Joseph Payne reported that interim Phase II data for ARCT-032, the company’s mRNA therapeutic candidate for cystic ...
San Diego-based RNA biotech Arcturus is doubling down on mRNA therapeutics and stepping back from earlier-stage vaccine work in an effort to prioritize spending and extend its cash runway. In a brief ...
In a mixed interim data drop, Arcturus Therapeutics has revealed a lack of efficacy for its investigational inhaled mRNA therapy in cystic fibrosis (CF). The findings, shared today before market open, ...
SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease ...
Sept 23 (Reuters) - Biotech company Arcturus Therapeutics (ARCT.O), opens new tab sued AbbVie (ABBV.N), opens new tab in California federal court on Tuesday for allegedly stealing trade secrets ...
Arcturus Therapeutics is transitioning from COVID-era revenues to milestone-driven growth, led by its mRNA platform and strategic partnerships. KOSTAIVE, ARCT's self-amplifying mRNA COVID-19 vaccine, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results